favorable-risk rcc: frontline vegf tki/io combinations
Published 4 years ago • 84 plays • Length 5:15Download video MP4
Download video MP3
Similar videos
-
4:27
vegf-tki therapy in first-line mrcc
-
4:09
favorable-risk rcc: options for vegf tki monotherapy
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
8:07
vegf tki immunotherapy combinations for mrcc
-
5:04
favorable-risk rcc: factors in selecting therapy
-
5:11
selecting immunotherapy versus vegf tki for mrcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:17:40
kcrs24 session six: immunotherapy advances in kidney cancer | kidneycan
-
38:47
renal cell carcinoma
-
55:12
selecting and sequencing targeted and immunotherapy regimens for patients with rcc
-
7:18
vegf tki therapy in the adjuvant setting of rcc
-
2:56
dr singer on the efficacy of io/tki doublets in advanced rcc
-
3:15
a novel approach: tki/i-o combinations in rcc
-
8:15
choosing an io/tki doublet for rcc patients: efficacy data, dosing, and more
-
1:02
current status of vegf inhibitor/immunotherapy combinations in rcc
-
9:16
frontline rcc treatment selection: io/io versus io/tki
-
10:37
patient scenarios and treatment considerations in the adjuvant rcc setting
-
51:09
immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: asco gu 2023
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:26:54
novel therapeutic strategies to individualize patient care in rcc: expert-led clinical consults
-
6:45
the latest data on io/tki versus io/io in frontline rcc